Incorporating ruthenium into advanced drug delivery carriers – an innovative generation of chemotherapeutics

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Chemical Technology & Biotechnology

• Publication date

  2015-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/JCTB.4507
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Polymers with platinum drugs and other macromolecular metal complexes for cancer treatment

  2014cited by this paper
• Poly(lactic acid) nanoparticles of the lead anticancer ruthenium compound KP1019 and its surfactant-mediated activation.

  2014cited by this paper
• Biophysical characterisation, antitumor activity and MOF encapsulation of a half-sandwich ruthenium(ii) mitoxantronato system.

  2014cited by this paper
• Ligand substitutions between ruthenium–cymene compounds can control protein versus DNA targeting and anticancer activity

  2014cited by this paper
• Superior Chemotherapeutic Benefits from the Ruthenium-Based Anti-Metastatic Drug NAMI-A through Conjugation to Polymeric Micelles

  2014cited by this paper
• Drug conjugation to cyclic peptide-polymer self-assembling nanotubes.

  2014cited by this paper
• The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics.

  2013cited by this paper
• A new design for nucleolipid-based Ru(III) complexes as anticancer agents.

  2013cited by this paper
• Features and full reversibility of the renal toxicity of the ruthenium-based drug NAMI-A in mice.

  2013cited by this paper
• Synthesis and cytotoxicity of a ruthenium nitrosyl nitric oxide donor with isonicotinic acid and a cell penetrating peptide

  2013cited by this paper
• Identification of the structural determinants for anticancer activity of a ruthenium arene peptide conjugate.

  2013cited by this paper
• Enhanced delivery of the RAPTA-C macromolecular chemotherapeutic by conjugation to degradable polymeric micelles.

  2013cited by this paper
• Transferrin serves as a mediator to deliver organometallic ruthenium(II) anticancer complexes into cells.

  2013cited by this paper
• Anticancer cationic ruthenium nanovectors: from rational molecular design to cellular uptake and bioactivity.

  2013cited by this paper
• Combination of metallomics and proteomics to study the effects of the metallodrug RAPTA-T on human cancer cells.

  2012cited by this paper
• Somatostatin subtype-2 receptor-targeted metal-based anticancer complexes.

  2012cited by this paper
• Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor.

  2012cited by this paper
• Complex polymer architectures via RAFT polymerization: From fundamental process to extending the scope using click chemistry and nature's building blocks

  2012cited by this paper
• Macromolecular ruthenium complexes as anti-cancer agents

  2012cited by this paper
• Block copolymer micelles with pendant bifunctional chelator for platinum drugs: effect of spacer length on the viability of tumor cells.

  2012cited by this paper
• Polymeric conjugates for drug delivery.

  2012cited by this paper
• Cholesterol-based nucleolipid-ruthenium complex stabilized by lipid aggregates for antineoplastic therapy.

  2012cited by this paper
• Ruthenium-based complex nanocarriers for cancer therapy.

  2012cited by this paper
• Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.

  2012cited by this paper
• Organometallic ruthenium(II) arene compounds with antiangiogenic activity.

  2011cited by this paper
• Photocontrolled DNA binding of a receptor-targeted organometallic ruthenium(II) complex.

  2011cited by this paper
• Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin.

  2011cited by this paper
• A ruthenium antimetastasis agent forms specific histone protein adducts in the nucleosome core.

  2011cited by this paper
• Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339

  2010cited by this paper
• In vitro Ruthenation of Human Breast Cancer Suppressor Gene 1 (BRCA1) by the Antimetastasis Compound RAPTA‐C and Its Analogue CarboRAPTA‐C

  2010cited by this paper
• Poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles containing chemically conjugated and physically entrapped docetaxel: synthesis, characterization, and the influence of the drug on micelle morphology.

  2010cited by this paper
• Activation Mechanisms for Organometallic Anticancer Complexes

  2010cited by this paper
• Ruthenium-based chemotherapeutics: are they ready for prime time?

  2010cited by this paper
• Grafting of water-soluble phosphines to dendrimers and their use in catalysis: positive dendritic effects in aqueous media.

  2009cited by this paper
• Influence of Structural Variation on the Anticancer Activity of RAPTA-Type Complexes: ptn versus pta

  2009cited by this paper
• Lipid based nanovectors containing ruthenium complexes: a potential route in cancer therapy.

  2009cited by this paper
• Recent developments in ruthenium anticancer drugs.

  2009cited by this paper
• Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt.

  2009cited by this paper
• Exploring metallodrug–protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound

  2009cited by this paper
• Unusual DNA binding modes for metal anticancer complexes.

  2009cited by this paper
• Metal Complex–DNA Interactions

  2009cited by this paper
• Reactivity of an antimetastatic organometallic ruthenium compound with metallothionein-2: relevance to the mechanism of action.

  2009cited by this paper
• Facile modification of 1,3,5-triaza-7-phosphatricyclo[3.3.1.1(3,7)]decane phosphanes coordinated to ruthenium(II).

  2009cited by this paper
• Ruthenium(II) Arene Compounds as Versatile Anticancer Agents

  2009cited by this paper
• The ruthenium(II)–arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53–JNK pathways

  2008cited by this paper
• RAFT polymerization: an avenue to functional polymeric micelles for drug delivery.

  2008cited by this paper
• Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound.

  2008cited by this paper
• Hydrolysis study of the bifunctional antitumour compound RAPTA-C, [Ru(eta6-p-cymene)Cl2(pta)].

  2008cited by this paper
• CZE-ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP.

  2008cited by this paper
• Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents.

  2008cited by this paper
• Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms.

  2007cited by this paper
• Ruthenium complexes can target determinants of tumour malignancy.

  2007cited by this paper
• Ruthenium Anticancer Compounds: Challenges and Expectations

  2007cited by this paper
• Ruthenium half-sandwich complexes as protein kinase inhibitors: derivatization of the pyridocarbazole pharmacophore ligand.

  2007cited by this paper
• Polymer therapeutics for cancer : Current status and future challenges

  2006cited by this paper
• Metal-based antitumour drugs in the post genomic era.

  2006cited by this paper
• Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery.

  2006cited by this paper
• Influence of Hydrogen-Bonding Substituents on the Cytotoxicity of RAPTA Compounds

  2006cited by this paper
• Microarrays for the Functional Analysis of the Chemical-Kinase Interactome

  2006cited by this paper
• Polymer conjugates as anticancer nanomedicines

  2006cited by this paper
• Classical and Non‐Classical Ruthenium‐Based Anticancer Drugs: Towards Targeted Chemotherapy

  2006cited by this paper
• From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).

  2006cited by this paper
• Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.

  2006cited by this paper
• Ruthenium complexes as anticancer agents.

  2006cited by this paper
• Selective estrogen receptor modulators in the ruthenocene series. Synthesis and biological behavior.

  2005cited by this paper
• In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.

  2005cited by this paper
• Switching on a signaling pathway with an organoruthenium complex.

  2005cited by this paper
• Development of organometallic (organo‐transition metal) pharmaceuticals

  2005cited by this paper
• Binding of Organometallic Ruthenium(II) and Osmium(II) Complexes to an Oligonucleotide: A Combined Mass Spectrometric and Theoretical Study

  2005cited by this paper
• Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy

  2004cited by this paper
• Prediction of aqueous solubility based on large datasets using several QSPR models utilizing topological structure representation.

  2004cited by this paper
• The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation.

  2004cited by this paper
• Coordination chemistry of 1,3,5-triaza-7-phosphaadamantane (PTA): Transition metal complexes and related catalytic, medicinal and photoluminescent applications

  2004cited by this paper
• Cocultures of metastatic and host immune cells: selective effects of NAMI-A for tumor cells

  2004cited by this paper
• Ruthenium antimetastatic agents.

  2004cited by this paper
• Use of chelating ligands to tune the reactive site of half-sandwich ruthenium(II)-arene anticancer complexes.

  2004cited by this paper
• Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms.

  2003cited by this paper
• Bipyrimidine photoproducts rather than oxidative lesions are the main type of DNA damage involved in the genotoxic effect of solar UVA radiation.

  2003cited by this paper
• Synthesis and characterisation of some water soluble ruthenium(II)–arene complexes and an investigation of their antibiotic and antiviral properties

  2003cited by this paper
• Minor Modifications to the Ligands Surrounding a Ruthenium Complex Lead to Major Differences in the Way in which they Catalyse the Hydrogenation of Arenes

  2003cited by this paper
• Distinct Effects of Dinuclear Ruthenium(III) Complexes on Cell Proliferation and on Cell Cycle Regulation in Human and Murine Tumor Cell Lines

  2003cited by this paper
• Regulation and mechanisms of mammalian double-strand break repair

  2003cited by this paper
• Kinetics of aquation and anation of ruthenium(II) arene anticancer complexes, acidity and X-ray structures of aqua adducts.

  2003cited by this paper
• In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer

  2002cited by this paper
• Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells

  2002cited by this paper
• Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A

  2002cited by this paper
• Intercalators as anticancer drugs.

  2001cited by this paper
• Advanced drug delivery devices via self-assembly of amphiphilic block copolymers.

  2001cited by this paper
• [Ru(η6-p-cymene)Cl2(pta)] (pta = 1,3,5-triaza-7-phosphatricyclo- [3.3.1.1]decane): a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells

  2001cited by this paper
• Mechanism of action in thalidomide teratogenesis.

  2000cited by this paper
• Non-platinum chemotherapeutic metallopharmaceuticals.

  1999cited by this paper
• New rhodium(I) water-soluble complexes with 1-alkyl-1-azonia-3,5-diaza-7-phospha-adamantane iodides and their catalytic activity

  1999cited by this paper
• Hydroxyl radicals and DNA base damage.

  1999cited by this paper
• Inhibition of topoisomerase II catalytic activity by two ruthenium compounds: a ligand-dependent mode of action.

  1999cited by this paper
• Chemical synthesis of polylactide and its copolymers for medical applications

  1998cited by this paper
• Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex

  1998cited by this paper
• Long circulating microparticulate drug carriers

  1995cited by this paper
• The genetic toxicology of acridines.

  1991cited by this paper
• A 31P NMR STUDY OF THE WATER SOLUBLE DERIVATIVES OF 1,3,5-TRIAZA-7-PHOSPHAADAMANTANE (PTA)

  1990cited by this paper
• Urinary 8-hydroxy-2'-deoxyguanosine as a biological marker of in vivo oxidative DNA damage.

  1989cited by this paper

• Rational Design of Enzyme-Responsive Fluorescent Organoruthenium Prodrug for Real-Time Tracking of Cargo Release and Cytotoxicity.

  2026cites this paper
• Review of the Most Important Research Trends in Potential Chemotherapeutics Based on Coordination Compounds of Ruthenium, Rhodium and Iridium

  2025cites this paper
• Ruthenium(II)–Arene Complexes with a 2,2′-Bipyridine Ligand as Anti-Aβ Agents

  2025cites this paper
• Recent advances in the metal/organic hybrid nanomaterials for cancer theranostics

  2024cites this paper
• Platinum Group Metals Nanoparticles in Breast Cancer Therapy

  2024cites this paper
• Effects induced by η6-p-cymene ruthenium(II) complexes on Langmuir monolayers mimicking cancer and healthy cell membranes do not correlate with their toxicity.

  2024cites this paper
• The Novel 5-Fluorouracil Loaded Ruthenium-based Nanocarriers Enhanced Anticancer and Apoptotic Efficiency while Reducing Multidrug Resistance in Colorectal Cancer Cells

  2023cites this paper
• From the Discovery of Targets to Delivery Systems: How to Decipher and Improve the Metallodrugs’ Actions at a Molecular Level

  2023cites this paper
• Synthesis and Anticancerogenic Effect of New Generation Ruthenium-Based Nanoparticle from Homalothecium sericeum with Eco-Friendly Method

  2023cites this paper
• Ruthenium (III)–Indigo Complex Loaded on the Salep Hydrogel as an Anti-inflammatory and Antioxidant Nanocomposite

  2023cites this paper
• Ruthenium(II) complexes bearing benzimidazole-based N-heterocyclic carbene (NHC) ligands as potential antimicrobial, antioxidant, enzyme inhibition, and antiproliferative agents

  2022cites this paper
• Dual drug delivery system of RAPTA-C and paclitaxel based on fructose coated nanoparticles for metastatic cancer treatment.

  2022cites this paper
• Polymeric Nanosystems Applied for Metal-Based Drugs and Photosensitizers Delivery: The State of the Art and Recent Advancements

  2022cites this paper
• Stimuli-Modulated Metal Oxidation States in Photochromic MOFs.

  2022cites this paper
• Versatile delivery systems for non-platinum metal-based anticancer therapeutic agents

  2021cites this paper
• Synthesis, Characterization, and Biological Activity of Water-Soluble, Dual Anionic and Cationic Ruthenium-Arene Complexes Bearing Imidazol(in)ium-2-dithiocarboxylate Ligands.

  2021cites this paper
• Polymers and Small-Molecule Ru Species

  2021cites this paper
• Polymers Incorporating Ru Complexes

  2021cites this paper
• Diatom-like silica-protein nanocomposites for sustained drug delivery of ruthenium polypyridyl complexes.

  2021cites this paper
• Labelled micelles for the delivery of cytotoxic Cu(II) and Ru(III) compounds in the treatment of aggressive orphan cancers: Design and biological in vitro data.

  2020cites this paper
• Ruthenium (II) complexes with N, O-chelating proline and threonine ligands cause selective cytotoxicity by the induction of genomic instability, cell cycle arrest and apoptosis in breast and prostate tumor cells.

  2020cites this paper
• Ruthenium Based Anticancer Compounds and Their Importance

  2020cites this paper
• Bioreducible and traceable Ru(III) prodrug-loaded mesoporous silica nanoparticles for sequentially targeted nonsmall cell lung cancer chemotherapy

  2020cites this paper
• Controlled Supramolecular Assembly Inside Living Cells by Sequential Multistaged Chemical Reactions

  2020cites this paper
• Experimental and theoretical characterization of the strong effects on DNA stability caused by half-sandwich Ru(II) and Ir(III) bearing thiabendazole complexes

  2020cites this paper
• Synthesis, Structural Characterization and Antimicrobial Evaluation of Ruthenium Complexes with Heteroaromatic Carboxylic Acids

  2019cites this paper
• Locked and Loaded: Ruthenium(II)-Capped Cucurbit[n]uril-Based Rotaxanes with Antimetastatic Properties.

  2019cites this paper
• Platinum(II) Complexes with 1,10‐Phenanthroline and Hydrophilic Alkoxyacetate Ligands as Potential Antitumor Agents

  2019cites this paper
• A Novel Conjugate of Bis[((4-Bromophenyl)amino)quinazoline], a EGFR-TK Ligand, with a Fluorescent Ru(II)-Bipyridine Complex, Exhibits Specific Subcellular Localization in Mitochondria.

  2019cites this paper
• Ru(II)-Based Amino Acid Complexes Show Promise for Leukemia Treatment: Cytotoxicity and Some Light on their Mechanism of Action

  2019cites this paper
• Anticancer Ruthenium(III) Complexes and Ru(III)-Containing Nanoformulations: An Update on the Mechanism of Action and Biological Activity

  2019cites this paper
• Polymer "ruthenium-cyclopentadienyl" conjugates - New emerging anti-cancer drugs.

  2019cites this paper
• Self-assembled ruthenium (II) metallacycles and metallacages with imidazole-based ligands and their in vitro anticancer activity

  2019cites this paper
• A new 3D organotypic model of ovarian cancer to help evaluate the antimetastatic activity of RAPTA-C conjugated micelles.

  2019cites this paper
• Poly(alkylidenimine) Dendrimers Functionalized with the Organometallic Moiety [Ru(η5-C5H5)(PPh3)2]+ as Promising Drugs Against Cisplatin-Resistant Cancer Cells and Human Mesenchymal Stem Cells

  2018cites this paper
• Strong Influence of Ancillary Ligands Containing Benzothiazole or Benzimidazole Rings on Cytotoxicity and Photoactivation of Ru(II) Arene Complexes.

  2018cites this paper
• DNA Binding Modes of Novel Terpyridine Ruthenium(II) Complexes Containing a Chloroquine Analogue

  2017cites this paper
• Synthesis and in vivo anticancer evaluation of poly(organo)phosphazene-based metallodrug conjugates.

  2017cites this paper
• The development of ruthenium(ii) polypyridyl complexes and conjugates for in vitro cellular and in vivo applications.

  2017cites this paper
• Nanoformulation as a Tool for Improve the Pharmacological Profile of Platinum and Ruthenium Anticancer Drugs

  2017cites this paper
• Cellular Uptake and Sensing Capability of Transition Metal Peptide Conjugates

  2017cites this paper
• RuIII Complexes for Anticancer Therapy: The Importance of Being Nucleolipidic

  2017cites this paper
• Vanadium, Ruthenium and Copper Compounds: A New Class of Nonplatinum Metallodrugs with Anticancer Activity.

  2017cites this paper
• Enhanced Antimetastatic Activity of the Ruthenium Anticancer Drug RAPTA-C Delivered in Fructose-Coated Micelles.

  2017cites this paper
• Frontier orbitals of photosubstitutionally active ruthenium complexes: an experimental study of the spectator ligands' electronic properties influence on photoreactivity.

  2017cites this paper
• Structural analysis of ruthenium-arene complexes using ion mobility mass spectrometry, collision-induced dissociation, and DFT.

  2016cites this paper
• Synthesis, characterization and biological evaluation of novel Ru(II)-arene complexes containing intercalating ligands.

  2016cites this paper
• A dual-fluorescent nano-carrier for delivering photoactive ruthenium polypyridyl complexes.

  2016cites this paper
• Synthesis of Gold(I) Derivatives Bearing Alkylated 1,3,5-Triaza-7-phosphaadamantane as Selective Anticancer Metallodrugs

  2016cites this paper
• Influence of the oxidation state of the metal center on the interaction of ruthenium complex with HSA

  2016cites this paper
• Copolymerization of an indazole ligand into the self-polymerization of dopamine for enhanced binding with metal ions.

  2015cites this paper
• Advances in Drug Delivery

  2015cites this paper